N/A
N=39
iTBS/fMRI Study of Hierarchical Control in the PFC
Transcranial Magnetic Stimulation
Bottom Line
View on ClinicalTrials.gov: NCT05878080 ↗Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: PFC-PPC Effective Connectivity — 0.2177; 0.2248; 0.1911; 0.3157 Hertz — p=0.599
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- transcranial magnetic stimulation (Device)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Florida State University
- Primary completion
- Dec 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PFC-PPC Effective Connectivity |
0.2177; 0.2248; 0.1911; 0.3157; 0.3168; 0.3153 | 0.599 |
| PRIMARY PFC-PPC Activation |
0.1649; 0.174; 0.1721; 0.0796; 0.0958; 0.1021 | 0.083 |
| SECONDARY Temporal Control Performance (Error Rate) |
3.6774; 4.6272; 3.9773; -0.9785; 0.0688; -0.7576 | 0.788 |
| SECONDARY Contextual Control Performance (Error Rate) |
7.7178; 4.7408; 5.7449; 2.5568; 2.3794; 2.399 | 0.119 |
| SECONDARY Temporal x Contextual Control Performance (Error Rate) |
-0.2367; -0.4449; -0.5051; 2.5568; 2.0457; 2.5884 | 0.985 |
| SECONDARY Temporal Control Performance (Reaction Time) |
14.7162; 1.3866; 2.3381; -49.5445; -49.5869; -65.4566 | 0.567 |
| SECONDARY Contextual Control Performance (Reaction Time) |
223.8835; 196.5144; 207.0607; 185.165; 151.2204; 172.9899 | 0.078 |
| SECONDARY Temporal x Contextual Control Performance (Reaction Time) |
73.9891; 62.1515; 73.5031; 174.2524; 157.9577; 161.0199 | 0.621 |
Summary
The objective of this study is to examine the effect of transcranial magnetic stimulation (TMS) on the prefrontal cortex and posterior parietal cortex.
Eligibility Criteria
Inclusion Criteria
- Between the ages of 18 and 30
- Right-handed
- Native English speaker or fluent by the age of 6
Exclusion Criteria
- History of psychiatric disorders
- History of neurological disorders
- Receiving medications for psychiatric or neurological disorders
- Familial history of epilepsy
- Taking any drugs or medications that are pro-epileptic
- Metal anywhere in the head excluding the mouth
- Tinnitus
- Women who are pregnant
Data sourced from ClinicalTrials.gov (NCT05878080). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.